A phase I, open-label, multi-dose, dose-escalation study of GW572016 [lapatinib] in patients with solid tumors-CNS
Latest Information Update: 26 Jun 2007
At a glance
- Drugs Lapatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 26 Jun 2007 New trial record.